Grounding coverage in value: A paradigm for linking quality and costs

Medical Care

Volumn 44, Issue 5, 2006, Pages 389-391

  Rosen, Allison B ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; ECONOMICS; EDITORIAL; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MASS COMMUNICATION; METHODOLOGY; THEORETICAL MODEL;

COST CONTROL; DIFFUSION OF INNOVATION; HEALTH EXPENDITURES; HUMANS; MODELS, THEORETICAL; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF HEALTH CARE;

EID: 33646763553     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000216191.86056.a1     Document Type: Editorial

References (24)

1. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-2645.
2. Rosenthal MB, Frank RG, Li Z, et al. Early experience with pay-for-performance: from concept to practice. JAMA. 2005;294:1788-1793.
3. Villagra V. Strategies to control costs and quality. A focus on outcomes research for disease management. Med Care. 2004;42:III-24-III-30.
4. Chernew ME, Rosen AB, Fendrick AM. Rising out-of-pocket costs in disease management programs: is anyone managing the co-pays? Am J Manag Care. 2006;12:150-154.
5. Centers for Medicare & Medicaid Services. National health accounts, 1960-2004. Available at: http://www.cms.hhs.gov/NationalHealthExpendData/ downloads/tables.pdf. Accessed February 14, 2006.
6. Kaiser Family Foundation. The uninsured: a primer. Publication no. 7451. Available at: http://www.kff.org/uninsured/upload/7451.pdf. Accessed February 16, 2006.
7. Cutler DM. Your Money or Your Life. New York: Oxford University Press; 2004.
8. Mah CA, Soumerai SB, Adams AS, et al. Racial differences in impact of coverage on diabetes self-monitoring in an HMO. Med Care. 2006;44:392-397.
9. Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Med Care Res Rev. 2004;61:415-452.
10. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11:730-740.
11. Newhouse J, the Insurance Experiment Group. Free for All? Lessons From the RAND Health Insurance Experiment. Cambridge, MA: Harvard University Press; 1993.
12. Fendrick AM, Smith SG, Chernew ME, et al. A benefit-based co-pay for prescription drugs: patient contribution based on total benefits, not on drug acquisition cost. Am J Manag Care. 2001;7:861-867.
13. Kleinke JD. Access versus excess: value-based cost sharing for prescription drugs. Health Aff (Millwood). 2004;23:34-47.
14. Fendrick AM, Chernew ME. Value-based insurance design: a 'clinically sensitive' approach to preserve quality of care and contain costs. Am J Manag Care. 2006;12:1-3.
15. Trude S, Grossman JM. Patient cost-sharing innovations: promises and pitfalls. Issue Brief No. 75. Washington, DC: Center for Studying Health System Change. Available at: http://www.hschange.org/. Accessed September 15, 2005.
16. Hensley S. From 'one size fits all' to tailored co-payments. Wall Street Journal. June 16, 2004.
17. Fuhrmans V. A radical prescription. Wall Street Journal. May 10, 2004:R3.
18. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43:173-184.
19. Payers raise the bar by lowering barriers to medications for chronically ill enrollees. Drug Benefit News. 2005;6:1-3.
20. Hayward RA, Kent DM, Vijan S, et al. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood). 2005;24:1571-1581.
21. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases. Implications for pay for performance. JAMA. 2005;294:716-724.
22. Coster S, Gulliford MC, Seed PT, et al. Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med. 2000;17:755-761.
23. Rosen AB, Hamel MB, Weinstein MC, et al. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
24. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12:21-28.